Abstract
Get full access to this article
View all access options for this article.
References
1.
Strawn
JR
,
Keck
PE
Jr
,
Caroff
SN
. Neuroleptic malignant syndrome . Am J Psychiatry , 2007 ; 164 (6 ):870 –876 .
2.
Picard
LS
,
Lindsay
S
,
Strawn
JR
,
Kaneria
RM
,
Patel
NC
,
Keck
PE
Jr
. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations . Pharmacotherapy . 2008 ; 28 (4 ):530 –535 .
3.
Stevens
DL
. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome . Ann Pharmacother , 2008 ; 42 (9 ):1290 –1297 .
4.
Adnet
P
,
Lestavel
P
,
Krivosic-Horber
R
. Neuroleptic malignant syndrome . Br J Anaesth , 2000 ; 85 (1 ):129 –135 .
5.
Carroll
BT
,
Surber
SA
. The problem of atypical neuroleptic malignant syndrome: a case report . Psychiatry (Edgmont) , 2009 ; 6 (7 ):45 –47 .
6.
Hermesh
H
,
Manor
I
,
Shiloh
R
, et al . High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome . J Clin Psychopharmacol , 2002 ; 22 (3 ):252 –256 .
7.
Susman
VL
. Clinical management of neuroleptic malignant syndrome . Psychiatr Q , 2001 ; 72 (4 ):325 –336 .
8.
Pelonero
AL
,
Levenson
JL
,
Pandurangi
AK
. Neuroleptic malignant syndrome: a review . Psychiatr Serv , 1998 ; 49 (9 ):1163 –1172 .
9.
Nicholson
D
,
Chiu
W
. Neuroleptic malignant syndrome . Geriatrics , 2004 ; 59 (8 ):36 , 38-40.
10.
Trollor
JN
,
Sachdev
PS
. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases . Aust N Z J Psychiatry , 1999 ; 33 (5 ):650 –659 .